European Hematology Association Congress | Conference

Ibrutinib Plus Venetoclax Produces High MRD Negativity Rate in Previously Untreated CLL

June 15th 2022

The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.

Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera

June 13th 2022

Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.

Dr. Short on Ponatinib and Blinatumomab in Philadelphia Chromosome–Positive ALL

June 13th 2022

Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Zanubrutinib Improves QOL Outcomes Vs Bendamustine/Rituximab in CLL/SLL

June 13th 2022

Zanubrutinib achieved favorable health-related quality of life outcomes compared with bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

REGN5458 Elicits Early, Sustainable Responses in Heavily Pretreated Multiple Myeloma

June 13th 2022

The bispecific antibody REGN5458 elicited rapid responses that were further characterized by their depth, durability, and low incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Parsaclisib Plus Ruxolitinib Demonstrates Splenic Volume Reduction in Myelofibrosis Irrespective of Platelet Count

June 13th 2022

Add-on parsaclisib and ruxolitinib elicited promising spleen volume reduction in patients with myelofibrosis who experienced suboptimal response to ruxolitinib alone, regardless of baseline platelet count, according to findings from a subgroup analysis of a phase 2 study.

Venetoclax Plus Obinutuzumab Confers Long-Term Survival Benefits in Unfit Patients With CLL

June 13th 2022

Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.

Ropeginterferon Alfa-2b Demonstrates Long-Term QOL Improvements in Polycythemia Vera

June 13th 2022

Treatment with ropeginterferon alfa-2b-njft induced low symptom burden and low phlebotomy requirement compared with best available treatment in patients with polycythemia vera, according to long-term data from the phase 3 PROUD-PV and CONTINUATION-PV trials.

Tisagenlecleucel Maintains Durable Response at 5 Years in Pediatric/Young Adult Patients With B-ALL

June 13th 2022

Long-term follow-up from the phase 2 ELIANA trial, showed that tisagenlecleucel continued to demonstrate durable efficacy in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Bezuclastinib Demonstrates Early Promise in Advanced Systemic Mastocytosis

June 13th 2022

Bezuclastinib showcased early signs of clinical activity in that it resulted in a meaningful reduction in serum tryptase levels, as well as reductions in mast cell burden and KIT D816V variant allele frequency, in adult patients with advanced systemic mastocytosis.

Talquetamab Plus Daratumumab Generates High Response Rate in CD38-Refractory Myeloma

June 12th 2022

The combination of talquetamab and daratumumab led to early onset and durable responses that deepened over time in patients with heavily pretreated multiple myeloma, most of whom were anti-CD38 refractory, according to findings from the phase 1b TRIMM-2 study.

Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

June 12th 2022

The combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response to ruxolitinib and in those who were JAK inhibitor naïve.

Dr. Al-Sawaf on the 5-Year Results of the CLL14 Trial in CLL

June 12th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

Frontline Subcutaneous Epcoritamab Plus R-CHOP Elicits ORR of 100% in High-Risk DLBCL

June 12th 2022

The combination of epcoritamab and R-CHOP produced high overall response rates and complete metabolic response rates with a manageable toxicity profile in patients with diffuse large B-cell lymphoma.

BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL

June 12th 2022

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.

Zandelisib Elicits High Response in Relapsed/Refractory Follicular Lymphoma

June 12th 2022

Zandelisib, a potent and selective oral PI3Kδ inhibitor, elicited a high overall response rate as a single agent in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to data from the phase 2 TIDAL trial.

Obinutuzumab/Chemo Maintains Superior PFS in Untreated Follicular Lymphoma at 8 Years

June 12th 2022

The combination of obinutuzumab plus chemotherapy delivered superior long-term progression-free survival benefit for patients with treatment-naïve follicular lymphoma.

R-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma

June 12th 2022

Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma.

Long-term Treatment With Luspatercept Reduces Transfusion Dependence Associated With β-Thalassemia

June 12th 2022

The longest duration of reduction in red blood cell transfusion dependence was reported among patients with β-thalassemia who received continued treatment with luspatercept-aamt in the updated data from the phase 3 BELIEVE trial.

Dr. Mascarenhas on Updates from the MANIFEST Trial in Myelofibrosis

June 11th 2022

John O. Mascarenhas, MD, discusses updates from the phase 2 MANIFEST trial in patients with myelofibrosis.